https://ntp.niehs.nih.gov/go/tox106abs

Abstract for TOX-106

Toxicity Studies of Sodium Metavanadate and Vanadyl Sulfate Administered in Drinking Water to Sprague Dawley (Hsd:Sprague Dawley SD) Rats and B6C3F1/N Mice

Substances:

  • Sodium metavanadate (CASRN 13718-26-8)
  • Vanadyl sulfate (CASRN 27774-13-6)

Report Date: February 2023

Full Report PDF

Abstract

Oral human exposure to vanadium may occur due to its presence in food and drinking water and its use in dietary supplements. The most prevalent oxidation states of vanadium in food and drinking water have been characterized as tetravalent and pentavalent. Vanadyl sulfate and sodium metavanadate were selected as representative tetravalent (V4+) and pentavalent (V5+) test articles for these studies, respectively. To assess the potential for oral toxicity of vanadium compounds with differing oxidation states under similar test conditions, the 3-month National Toxicology Program (NTP) toxicity studies of sodium metavanadate and vanadyl sulfate were conducted in male and female Sprague Dawley (Hsd:Sprague Dawley SD) rats (including perinatal exposure) and in B6C3F1/N mice. Drinking water concentrations for sodium metavanadate (0, 31.3, 62.5, 125, 250, and 500 mg/L) and vanadyl sulfate (0, 21.0, 41.9, 83.8, 168, and 335 mg/L) were selected on the basis of previously published 14-day drinking water studies conducted as part of the NTP vanadium research program.

During the perinatal phase of the rat sodium metavanadate study, dams and pups exposed to the highest concentrations had lower survival. Moribund dams were removed beginning on gestation day 22, and select dams and pups continued to be removed due to moribundity or mortality throughout the lactation period. These removals collectively resulted in four litters in the 500 mg/L sodium metavanadate group available to populate the postweaning study. There were no effects on survival of vanadyl sulfate-exposed dams or pups.

In the perinatal and 3-month rat studies, 10 F1 pups/sex/group were selected for continuation during the postweaning phase; all available pups (n = 12 or 13) were retained in the 500 mg/L group for the sodium metavanadate study. In the 3-month mouse studies, 10 animals per sex were assigned to each exposure group. Lower water consumption was observed in both rats and mice at the highest exposure concentrations for both test articles. Lower body weights were observed at the end of the 3-month studies in rats and mice exposed to sodium metavanadate and in mice exposed to vanadyl sulfate. Absolute thymus weights were decreased in male and female mice exposed to sodium metavanadate. Several other organ weight changes occurred in these studies and were considered secondary to body weight changes.

For rats and mice exposed to sodium metavanadate and mice exposed to vanadyl sulfate, hematological effects related to erythrocyte microcytosis, including decreased mean cell volume, were consistently observed. This response was more severe in mice, with corresponding reductions in hematocrit and hemoglobin as well as an erythrocytosis response, including increased erythrocytes and reticulocytes. In sodium metavanadate-exposed rats, decreased globulin and cholesterol were observed. Epithelial hyperplasia of the ileum was observed in rats and mice exposed to sodium metavanadate and vanadyl sulfate. This lesion was not observed in any control animals. Other sites of the small or large intestine, including the jejunum, were observed to have epithelial hyperplasia, but these observations were not consistent across test articles or sex/species.

Vanadium intake was calculated using the amount of vanadium in each test article (41.7% in sodium metavanadate and 31% in vanadyl sulfate), the exposure concentration, and the measured water consumption. In rats, the overall lowest-observed-effect levels (LOELs) for both sodium metavanadate and vanadyl sulfate align well with vanadium intake, indicating that total vanadium, rather than vanadium oxidation state, may be a driver for toxicity. In mice, however, the overall LOELs for both compounds and the LOELs for specific endpoints do not occur at the same calculated vanadium doses between test articles.

Sodium metavanadate and vanadyl sulfate were not mutagenic in several bacterial tester strains, with or without exogenous metabolic activation (S9 mix), and no biologically significant increases in micronucleated reticulocytes were seen in male and female rats and mice. An increase in the percentage of circulating immature erythrocytes (reticulocytes) was seen in male rats and in male and female mice when exposed to sodium metavanadate, whereas there were no changes in this population of cells in female rats. When exposed to vanadyl sulfate, increases in the percentage of reticulocytes were seen in male and female mice; however, no notable changes in this population of cells were observed in male and female rats.

Under the conditions of these studies, oral exposure to sodium metavanadate or vanadyl sulfate in drinking water resulted in hematological effects associated with erythrocyte microcytosis in rats (sodium metavanadate) and mice (sodium metavanadate and vanadyl sulfate), including erythrocytosis in male rats and in male and female mice. Epithelial hyperplasia of the ileum and other gastrointestinal sites was observed histologically, which was consistent for both test articles and across both sexes and species evaluated. In the sodium metavanadate studies, the LOELs were 125 mg/L in male and female rats, 31.3 mg/L in male mice, and 62.5 mg/L in female mice, based on changes in hematology (male rats and male and female mice) and epithelium hyperplasia in the ileum and jejunum (male and female rats). In the vanadyl sulfate studies, the LOELs were 168 mg/L in male and female rats and 83.8 mg/L in male and female mice, as indicated by epithelium hyperplasia in the ileum (male and female rats and mice) and hematology (female mice).

National Toxicology Program (NTP). 2023. NTP technical report on the toxicity studies of sodium metavanadate (CASRN 13718-26-8) and vanadyl sulfate (CASRN 27774-13-6) administered in drinking water to Sprague Dawley (Hsd:Sprague Dawley SD) rats and B6C3F1/N mice. Research Triangle Park, NC: National Toxicology Program. Toxicity Report 106. https://doi.org/10.22427/NTP-TOX-106

Studies

Summary of Findings Considered Toxicologically Relevant in Male and Female Rats and Mice Exposed to Sodium Metavanadate or Vanadyl Sulfate in Drinking Water for Three Months
  Male
Sprague Dawley Rats
Female
Sprague Dawley Rats
Male
B6C3F1/N Mice
Female
B6C3F1/N Mice
Concentrations in drinking water

Sodium metavanadate

0, 31.3, 62.5, 125, 250, or 500 mg/L 0, 31.3, 62.5, 125, 250, or 500 mg/L 0, 31.3, 62.5, 125, 250, or 500 mg/L 0, 31.3, 62.5, 125, 250, or 500 mg/L

Vanadyl sulfate

0, 21.0, 41.9, 83.8, 168, or 335 mg/L 0, 21.0, 41.9, 83.8, 168, or 335 mg/L 0, 21.0, 41.9, 83.8, 168, or 335 mg/L 0, 21.0, 41.9, 83.8, 168, or 335 mg/L
Survival rates

Sodium metavanadate

15/15, 15/15, 15/15, 15/15, 15/15, 12/13 15/15, 15/15, 15/15, 15/15, 15/15, 10/12 No effect[a] No effect[a]

Vanadyl sulfate

No effect No effect No effect No effect
Body weights

Sodium metavanadate

F1 generation: Lactation: ↓ (125, 250, 500 mg/L groups: up to 21% lower than the control group)

Study termination: ↓ (125, 250, and 500 mg/L groups: up to 27% lower than the control group)
F0 generation: Gestation: ↓ (125, 250, and 500 mg/L groups: up to 14% lower than the control group)

Lactation: No effect

F1 generation: Lactation: ↓ (500 mg/L group: 22% lower than the control group)

Study termination: ↓ (500 mg/L group 11% lower than the control group)
↓ (250 and 500 mg/L groups: 11% and 26% lower than the control group, respectively) ↓ (250 and 500 mg/L groups: 14% and 23% lower than the control group, respectively)

Vanadyl sulfate

F1 generation: Lactation: Exposed groups within 10% of the control group

Study termination: Exposed groups within 10% of the control group
F0 generation: Gestation: Exposed groups within 10% of the control group

Lactation: No effect

F1 generation: Lactation: Exposed groups within 10% of the control group

Study termination: No effect
↓ (168 and 335 mg/L groups: 10% and 13% lower than the control group, respectively) No effect
Clinical findings
Sodium metavanadate Ruffled coat, hunched, lethargy Ruffled coat, hunched, lethargy None[b] None
Vanadyl sulfate None None None None
Water consumption
Sodium metavanadate 250 and 500 mg/L groups: 11% and 16% lower than the control group, respectively 250 and 500 mg/L groups: 19% and 28% lower than the control group, respectively 500 mg/L group: 15% lower than the control group 500 mg/L group: 15% lower than the control group
Vanadyl sulfate 83.8, 168, and 335 mg/L groups: up to 21% lower than the control group 335 mg/L group: 24% lower than the control group 335 mg/L group: 10% lower than the control group 21.0, 41.9, 83.8, 168, and 335 mg/L groups: up to 17% lower than the control group
Organ weights
Sodium metavanadate No effect No effect ↓ Absolute thymus weight ↓ Absolute thymus weight
Vanadyl sulfate No effect No effect No effect No effect
Nonneoplastic effects
Sodium metavanadate Small intestine: ileum, epithelium, hyperplasia (0/10, 0/10, 0/9, 5/9, 9/10, 12/13); jejunum, epithelium, hyperplasia (0/10, –[c], 0/9, 1/9, 6/10, 7/13) Small intestine: ileum, epithelium, hyperplasia (0/9, –, 0/10, 4/10, 9/10, 12/12); jejunum, epithelium, hyperplasia (0/9, –, –, 1/10, 0/10, 6/12) Small intestine: ileum, epithelium, hyperplasia (0/10, –, 0/10, 2/10, 5/10, 7/10) Small intestine: ileum, epithelium, hyperplasia (0/10, –, 0/10, 2/10, 9/10, 8/10)
Vanadyl sulfate Small intestine: ileum, epithelium, hyperplasia (0/10, –, –, –, 3/10, 9/10) Small intestine: ileum, epithelium, hyperplasia (0/10, –, 0/10, 0/10, 4/10, 9/10) Small intestine: ileum, epithelium, hyperplasia (0/10, –, 0/9, 2/9, 3/10, 9/10) Small intestine: ileum, epithelium, hyperplasia (0/10, –, 0/10, 1/9, 5/10, 10/10)
Hematology
Sodium metavanadate ↑ Erythrocytes
↓ Mean cell volume
↓ Mean cell hemoglobin concentration
↑ Erythrocytes
↓ Mean cell volume
↓ Mean cell hemoglobin concentration
↑ Erythrocytes
↑ Reticulocytes
↓ Mean cell volume
↓ Hematocrit
↓ Hemoglobin
↑ Erythrocytes
↑ Reticulocytes
↓ Mean cell volume
↓ Hemoglobin
Vanadyl sulfate None None ↑ Reticulocytes
↓ Mean cell volume
↓ Mean cell hemoglobin concentration
↓ Hemoglobin
↑ Erythrocytes
↓ Mean cell volume
↓ Mean cell hemoglobin concentration
Clinical chemistry
Sodium metavanadate ↓ Globulin
↓ Cholesterol
↓ Globulin
↓ Cholesterol
Vanadyl sulfate No effect No effect
Reproductive findings
Sodium metavanadate No effect No effect No effect No effect
Vanadyl sulfate No effect No effect No effect No effect
Pubertal endpoints
Vaginal opening
Sodium metavanadate Delayed (250 mg/L)
Vanadyl sulfate Delayed (335 mg/L)
Genetic Toxicology
Assay Results
Bacterial mutagenicity:
 

Negative in Salmonella typhimurium strains TA98 and TA100 and Escherichia coli strain WP2 uvrA (pKM101), with and without S9

Micronucleated erythrocytes (in vivo)
Rat peripheral blood:


Mouse peripheral blood:


Sodium metavanadate: negative in males and females
Vanadyl sulfate: negative in males and females

Sodium metavanadate: negative in males and females
Vanadyl sulfate: negative in males and females


[a] One male and one female mouse exposed to 500 mg/L and 250 mg/L sodium metavanadate, respectively, died during the study; however, these deaths were not considered exposure related.
[b] None = no toxicologically relevant effects for this endpoint.
[c] Data were not collected for an exposed group when animals exposed to higher concentrations exhibited no incidences of nonneoplastic lesions in that tissue.